HCV neutralization goes elite
- PMID: 35139349
- DOI: 10.1016/j.immuni.2022.01.010
HCV neutralization goes elite
Abstract
A vaccine remains the most promising option to eradicate HCV. In this issue of Immunity, Weber et al. identified HCV elite neutralizers, isolated exceptionally potent and broad VH1-69 CD81-binding site neutralizing antibodies that used a shared mode of antigen recognition, and developed a computational approach that predicted mutations relevant to gain-of-function for this bnAb class, which can inform immunogen designs.
Published by Elsevier Inc.
Conflict of interest statement
Declaration of interests The authors declare no competing interests.
Comment on
-
Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization.Immunity. 2022 Feb 8;55(2):341-354.e7. doi: 10.1016/j.immuni.2021.12.003. Epub 2022 Jan 5. Immunity. 2022. PMID: 34990590 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical